v3.25.3

Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Income Statement [Abstract]
Revenue	$ 7,608	$ (7,676)	$ 25,482	$ 24,554
Operating expenses:
Research and development	45,874	41,197	129,965	115,037
General and administrative	18,087	15,042	54,433	42,887
Total operating expenses	63,961	56,239	184,398	157,924
Loss from operations	(56,353)	(63,915)	(158,916)	(133,370)
Other income, net:
Interest income	2,177	1,798	7,424	6,425
Other income (expense), net	324	337	293	684
Total other income, net	2,501	2,135	7,717	7,109
Loss before income taxes	(53,852)	(61,780)	(151,199)	(126,261)
Income tax benefit (provision)	0	0	0	0
Net loss	$ (53,852)	$ (61,780)	$ (151,199)	$ (126,261)
Net loss per share attributable to ordinary shareholders - basic	$ (0.32)	$ (0.47)	$ (0.92)	$ (0.97)
Net loss per share attributable to ordinary shareholders - diluted	$ (0.32)	$ (0.47)	$ (0.92)	$ (0.97)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders - basic	167,739,208	132,563,467	164,773,525	130,470,603
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders - diluted	167,739,208	132,563,467	164,773,525	130,470,603
Other comprehensive loss:
Net Income (Loss)	$ (53,852)	$ (61,780)	$ (151,199)	$ (126,261)
Foreign currency translation	(29)	120	72	(35)
Comprehensive loss	$ (53,881)	$ (61,660)	$ (151,127)	$ (126,296)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5

Wave Life Sciences Ltd. 10-Q